In the past week, TVGN stock has gone down by -29.09%, with a monthly decline of -41.58% and a quarterly plunge of -57.12%. The volatility ratio for the week is 13.13%, and the volatility levels for the last 30 days are 12.26% for Tevogen Bio Holdings Inc. The simple moving average for the past 20 days is -30.65% for TVGN’s stock, with a -91.40% simple moving average for the past 200 days.
Is It Worth Investing in Tevogen Bio Holdings Inc. (NASDAQ: TVGN) Right Now?
The 36-month beta value for TVGN is at 0.31. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for TVGN is 20.88M, and currently, shorts hold a 3.30% of that float. The average trading volume for TVGN on October 02, 2024 was 219.60K shares.
TVGN) stock’s latest price update
Tevogen Bio Holdings Inc. (NASDAQ: TVGN)’s stock price has dropped by -17.24 in relation to previous closing price of 0.37. Nevertheless, the company has seen a loss of -29.09% in its stock price over the last five trading days. globenewswire.com reported 2024-09-24 that WARREN, N.J., Sept. 24, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, shared the company’s ambition to address the Long COVID crisis as its leadership met with Congress on Capitol Hill last week.
TVGN Trading at -44.29% from the 50-Day Moving Average
After a stumble in the market that brought TVGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.55% of loss for the given period.
Volatility was left at 12.26%, however, over the last 30 days, the volatility rate increased by 13.13%, as shares sank -35.27% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -60.59% lower at present.
During the last 5 trading sessions, TVGN fell by -29.09%, which changed the moving average for the period of 200-days by -97.23% in comparison to the 20-day moving average, which settled at $0.4314. In addition, Tevogen Bio Holdings Inc. saw -97.26% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TVGN starting from Desai Kirti, who purchase 3,000 shares at the price of $0.82 back on Jun 12 ’24. After this action, Desai Kirti now owns 9,699,186 shares of Tevogen Bio Holdings Inc., valued at $2,460 using the latest closing price.
Saadi Ryan H., the Chief Executive Officer of Tevogen Bio Holdings Inc., purchase 2,607 shares at $0.77 during a trade that took place back on Jun 05 ’24, which means that Saadi Ryan H. is holding 118,252,659 shares at $2,000 based on the most recent closing price.
Stock Fundamentals for TVGN
The total capital return value is set at 5.39. Equity return is now at value 268.90, with 22.57 for asset returns.
Based on Tevogen Bio Holdings Inc. (TVGN), the company’s capital structure generated -0.36 points at debt to capital in total, while cash flow to debt ratio is standing at -3.0. The debt to equity ratio resting at -0.26. The interest coverage ratio of the stock is -95.6.
Currently, EBITDA for the company is -2.27 million with net debt to EBITDA at 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.23.
Conclusion
In conclusion, Tevogen Bio Holdings Inc. (TVGN) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
